BAYLOR COLLEGE OF MEDICINE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1900-10-30
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.bcm.edu
Randomized Clinical Trial of Early Delivery in Fetal Gastroschisis vs. Routine Care
Not Applicable
Terminated
- Conditions
- Gastroschisis
- Interventions
- Other: Early Delivery
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT01884324
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
MER Versus MRI Guidance DBS in Parkinson's Disease
Completed
- Conditions
- Idiopathic Parkinson's Disease (PD)
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT01883973
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea
Phase 1
- Conditions
- Active C. Difficile Colitis
- Interventions
- Biological: Microbiota Transplantation (FMT)
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT01868373
- Locations
- 🇺🇸
Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, United States
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
Phase 2
Completed
- Conditions
- Hodgkin Disease
- Interventions
- Drug: ABVE-PCDrug: DECA
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT01858922
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Phase 1
Recruiting
- Conditions
- Acute Lymphocytic LeukemiaNon-Hodgkin LymphomaChronic Lymphocytic Leukemia
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 64
- Registration Number
- NCT01853631
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
Video Games for Obesity and Diabetes Prevention-Diab & Nano
Not Applicable
Completed
- Conditions
- ObesityType 2 Diabetes
- Interventions
- Behavioral: G4H-Diab-Nano
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 200
- Registration Number
- NCT01846377
- Locations
- 🇺🇸
Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas, United States
3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Phase 1
Active, not recruiting
- Conditions
- Neuroblastoma
- Interventions
- Genetic: iC9-GD2 T Cells - frozenGenetic: iC9-GD2 T Cells - freshDrug: CytoxanDrug: FludaraDrug: KeytrudaGenetic: iC9-GD2 T cells
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT01822652
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
Eosinophilic Esophagitis Clinical Therapy Comparison Trial
Phase 2
Terminated
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Drug: Oral BudesonideOther: Elimination diet
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 3
- Registration Number
- NCT01821898
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Phase 4
Completed
- Conditions
- HyperglycemiaDiabetes Mellitus
- Interventions
- Drug: Glargine insulinDrug: Lispro insulinDrug: NPH Insulin
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 37
- Registration Number
- NCT01810952
- Locations
- 🇺🇸
St. Luke's Episcopal Hospital, Houston, Texas, United States
Effects of Dry Eye Treatments on the Ocular Surface
Phase 4
Completed
- Conditions
- Dry Eye SyndromeKeratoconjunctivitis Sicca
- Interventions
- Drug: DexamethasoneDrug: Artificial tear
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT01797822
- Locations
- 🇺🇸
Baylor College of Medicine, Alkek Eye Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath